With the advantage of broad patient population, accelerated patient recruitment, high trial quality and reasonable costs, the company provides a strong presence as a leading CRO in China, offering full service Phase I - IV clinical trials.
As the first international CRO to enter China, it has conducted more than 60 studies in China since 1997. Currently, it provides a strategic base of operations in Beijing, China, with highly qualified, dedicated CRAs, all extensively trained in compliance with ICH GCP standards. All of its clinical monitoring staff holds a medical and/or pharmacy degree.
Kendle (Nasdaq: KNDL) is among the world’s leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from “first-in-human” studies through market launch and surveillance -- to help the world’s biopharmaceutical companies maximize product life cycles and grow market share.
Kendle has a 25-year history of serving customers, both large and small, and with a diversity of compounds, which means that its expertise spans every major therapeutic area. It is focused on growing Phase I-IV clinical development expertise in the top five therapeutic areas expected to represent 70 percent of R&D spending by 2009: cardiology, oncology, antibiotics and antivirals, central nervous system and arthritis/inflammation.
With headquarters in Cincinnati, Ohio and approximately 3,000 associates worldwide, Kendle has conducted clinical trials or provided regulatory services in 80 countries.